{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T13:19:11Z","timestamp":1791638351045,"version":"4.3.4"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":27,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Xinjiang Uygur Autonomous Region Natural Science Foundation for Youth","award":["2025D01C432"],"award-info":[{"award-number":["2025D01C432"]}]},{"name":"Key research and development project of Xinjiang Uygur Autonomous Region","award":["2022B03022-4"],"award-info":[{"award-number":["2022B03022-4"]}]},{"name":"\"Tianshan Talents\" training program","award":["2022TSYCLJ0030"],"award-info":[{"award-number":["2022TSYCLJ0030"]}]},{"DOI":"10.13039\/501100001809","name":"The National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82460097"],"award-info":[{"award-number":["82460097"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"The Key Project of Xinjiang Natural Science Foundation","award":["2024D01D22"],"award-info":[{"award-number":["2024D01D22"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"DOI":"10.1186\/s12872-026-05502-8","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T09:34:03Z","timestamp":1768296843000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cumulative LDL cholesterol exposure and the risk of coronary artery lesion progression: a linear association"],"prefix":"10.1186","volume":"26","author":[{"given":"Menglong","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyan","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,13]]},"reference":[{"issue":"34","key":"5502_CR1","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"FLJ Visseren","year":"2021","unstructured":"Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, B\u00e4ck M, Benetos A, Biffi A, Boavida J-M, Capodanno D, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227\u2013337.","journal-title":"Eur Heart J"},{"issue":"4","key":"5502_CR2","first-page":"e201635","volume":"2016","author":"MA Kashef","year":"2016","unstructured":"Kashef MA, Giugliano G. Legacy effect of statins: 20-year follow up of the West of Scotland coronary prevention study (WOSCOPS). Glob Cardiol Sci Pract. 2016;2016(4):e201635.","journal-title":"Glob Cardiol Sci Pract"},{"issue":"20","key":"5502_CR3","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1093\/eurheartj\/ehr333","volume":"32","author":"PS Sever","year":"2011","unstructured":"Sever PS, Chang CL, Gupta AK, Whitehouse A, Poulter NR. The Anglo-Scandinavian cardiac outcomes trial: 11-year mortality follow-up of the lipid-lowering arm in the U.K. Eur Heart J. 2011;32(20):2525\u201332.","journal-title":"Eur Heart J"},{"issue":"9315","key":"5502_CR4","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/S0140-6736(02)08351-4","volume":"359","author":"Long-term effectiveness","year":"2002","unstructured":"Long-term effectiveness. And safety of Pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up. Lancet. 2002;359(9315):1379\u201387.","journal-title":"Lancet"},{"issue":"9","key":"5502_CR5","doi-asserted-by":"publisher","first-page":"e72642","DOI":"10.1371\/journal.pone.0072642","volume":"8","author":"SM Lloyd","year":"2013","unstructured":"Lloyd SM, Stott DJ, de Craen AJ, Kearney PM, Sattar N, Perry I, Packard CJ, Briggs A, Marchbank L, Comber H, et al. Long-term effects of Statin treatment in elderly people: extended follow-up of the prospective study of Pravastatin in the elderly at risk (PROSPER). PLoS ONE. 2013;8(9):e72642.","journal-title":"PLoS ONE"},{"issue":"13","key":"5502_CR6","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1056\/NEJMoa0804602","volume":"359","author":"AB Rosseb\u00f8","year":"2008","unstructured":"Rosseb\u00f8 AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, Gerdts E, Gohlke-B\u00e4rwolf C, Holme I, Kes\u00e4niemi YA, et al. Intensive lipid Lowering with Simvastatin and Ezetimibe in aortic stenosis. N Engl J Med. 2008;359(13):1343\u201356.","journal-title":"N Engl J Med"},{"issue":"9784","key":"5502_CR7","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","volume":"377","author":"C Baigent","year":"2011","unstructured":"Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, et al. The effects of Lowering LDL cholesterol with Simvastatin plus Ezetimibe in patients with chronic kidney disease (Study of heart and renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377(9784):2181\u201392.","journal-title":"Lancet"},{"issue":"25","key":"5502_CR8","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, et al. Ezetimibe added to Statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387\u201397.","journal-title":"N Engl J Med"},{"issue":"18","key":"5502_CR9","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713\u201322.","journal-title":"N Engl J Med"},{"issue":"22","key":"5502_CR10","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097\u2013107.","journal-title":"N Engl J Med"},{"issue":"9493","key":"5502_CR11","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","volume":"366","author":"C Baigent","year":"2005","unstructured":"Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of Statins. Lancet. 2005;366(9493):1267\u201378.","journal-title":"Lancet"},{"issue":"9753","key":"5502_CR12","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"C Baigent","year":"2010","unstructured":"Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, et al. Efficacy and safety of more intensive Lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670\u201381.","journal-title":"Lancet"},{"issue":"22","key":"5502_CR13","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1056\/NEJMoa1604304","volume":"375","author":"BA Ference","year":"2016","unstructured":"Ference BA, Robinson JG, Brook RD, Catapano AL, Chapman MJ, Neff DR, Voros S, Giugliano RP, Davey Smith G, Fazio S, et al. Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes. N Engl J Med. 2016;375(22):2144\u201353.","journal-title":"N Engl J Med"},{"issue":"15","key":"5502_CR14","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1016\/j.jacc.2015.02.020","volume":"65","author":"BA Ference","year":"2015","unstructured":"Ference BA, Majeed F, Penumetcha R, Flack JM, Brook RD. Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 \u00d7 2 factorial Mendelian randomization study. J Am Coll Cardiol. 2015;65(15):1552\u201361.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"5502_CR15","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1001\/jama.2018.20045","volume":"321","author":"BA Ference","year":"2019","unstructured":"Ference BA, Kastelein JJP, Ray KK, Ginsberg HN, Chapman MJ, Packard CJ, Laufs U, Oliver-Williams C, Wood AM, Butterworth AS, et al. Association of Triglyceride-Lowering LPL variants and LDL-C-Lowering LDLR variants with risk of coronary heart disease. JAMA. 2019;321(4):364\u201373.","journal-title":"JAMA"},{"issue":"32","key":"5502_CR16","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","volume":"38","author":"BA Ference","year":"2017","unstructured":"Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, Hegele RA, Krauss RM, Raal FJ, Schunkert H, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European atherosclerosis society consensus panel. Eur Heart J. 2017;38(32):2459\u201372.","journal-title":"Eur Heart J"},{"issue":"25","key":"5502_CR17","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1016\/j.jacc.2012.09.017","volume":"60","author":"BA Ference","year":"2012","unstructured":"Ference BA, Yoo W, Alesh I, Mahajan N, Mirowska KK, Mewada A, Kahn J, Afonso L, Williams KA, Sr., Flack JM. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. J Am Coll Cardiol. 2012;60(25):2631\u20139.","journal-title":"J Am Coll Cardiol"},{"issue":"45","key":"5502_CR18","doi-asserted-by":"publisher","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","volume":"34","author":"BG Nordestgaard","year":"2013","unstructured":"Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, Wiklund O, Hegele RA, Raal FJ, Defesche JC, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European atherosclerosis society. Eur Heart J. 2013;34(45):3478\u2013a3490.","journal-title":"Eur Heart J"},{"issue":"32","key":"5502_CR19","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","volume":"35","author":"M Cuchel","year":"2014","unstructured":"Cuchel M, Bruckert E, Ginsberg HN, Raal FJ, Santos RD, Hegele RA, Kuivenhoven JA, Nordestgaard BG, Descamps OS, Steinhagen-Thiessen E, et al. Homozygous Familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the consensus panel on Familial hypercholesterolaemia of the European atherosclerosis society. Eur Heart J. 2014;35(32):2146\u201357.","journal-title":"Eur Heart J"},{"issue":"8","key":"5502_CR20","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/S0002-9149(97)89309-5","volume":"77","author":"HH Schmidt","year":"1996","unstructured":"Schmidt HH, Hill S, Makariou EV, Feuerstein IM, Dugi KA, Hoeg JM. Relation of cholesterol-year score to severity of calcific atherosclerosis and tissue deposition in homozygous Familial hypercholesterolemia. Am J Cardiol. 1996;77(8):575\u201380.","journal-title":"Am J Cardiol"},{"issue":"13","key":"5502_CR21","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1016\/j.jacc.2020.08.004","volume":"76","author":"MD Shapiro","year":"2020","unstructured":"Shapiro MD, Bhatt DL. Cholesterol-Years for ASCVD risk prediction and treatment. J Am Coll Cardiol. 2020;76(13):1517\u201320.","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"5502_CR22","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1016\/j.jacc.2020.07.059","volume":"76","author":"MJ Domanski","year":"2020","unstructured":"Domanski MJ, Tian X, Wu CO, Reis JP, Dey AK, Gu Y, Zhao L, Bae S, Liu K, Hasan AA, et al. Time course of LDL cholesterol exposure and cardiovascular disease event risk. J Am Coll Cardiol. 2020;76(13):1507\u201316.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"5502_CR23","first-page":"770","volume":"28","author":"C Jing","year":"2024","unstructured":"Jing C, Rulin M, Jia H, Dongsheng R, Yu L, Xianghui Z, Leyao J, Jiahang L, Shuxia G, Heng G. A cohort study of the effect cumulative exposure to LDL-C on cardiovascular disease among the Uygur population in Southern Xinjiang. Chin J Dis Control Prev. 2024;28(7):770\u20136.","journal-title":"Chin J Dis Control Prev"},{"issue":"8033","key":"5502_CR24","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41586-024-07993-x","volume":"634","author":"M Takaoka","year":"2024","unstructured":"Takaoka M, Zhao X, Lim HY, Magnussen CG, Ang O, Suffee N, Schrank PR, Ong WS, Tsiantoulas D, Sommer F, et al. Early intermittent hyperlipidaemia alters tissue macrophages to fuel atherosclerosis. Nature. 2024;634(8033):457\u201365.","journal-title":"Nature"},{"key":"5502_CR25","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.atherosclerosis.2022.11.011","volume":"364","author":"AO Agbaje","year":"2023","unstructured":"Agbaje AO, Lloyd-Jones DM, Magnussen CG, Tuomainen TP. Cumulative dyslipidemia with arterial stiffness and carotid IMT progression in asymptomatic adolescents: A simulated intervention longitudinal study using Temporal inverse allocation model. Atherosclerosis. 2023;364:39\u201348.","journal-title":"Atherosclerosis"},{"issue":"1","key":"5502_CR26","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1186\/s12872-024-03977-x","volume":"24","author":"W Huang","year":"2024","unstructured":"Huang W, Nie W, Zhao J, Fan Z, Wang D, Wu X, Hao Y, Wu S. The association of cumulative low-density lipoprotein cholesterol exposure and carotid intima-media thickness in a young adulthood population. BMC Cardiovasc Disord. 2024;24(1):318.","journal-title":"BMC Cardiovasc Disord"},{"issue":"2","key":"5502_CR27","doi-asserted-by":"publisher","first-page":"e238","DOI":"10.1016\/j.jacl.2023.12.006","volume":"18","author":"T Yamaji","year":"2024","unstructured":"Yamaji T, Yusoff FM, Kishimoto S, Kajikawa M, Yoshimura K, Nakano Y, Goto C, Harada T, Mizobuchi A, Tanigawa S, et al. Association of cumulative low-density lipoprotein cholesterol exposure with vascular function. J Clin Lipidol. 2024;18(2):e238\u201350.","journal-title":"J Clin Lipidol"},{"issue":"17","key":"5502_CR28","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1001\/jama.290.17.2292","volume":"290","author":"SE Nissen","year":"2003","unstructured":"Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, Eaton GM, Lauer MA, Sheldon WS, Grines CL, et al. Effect of Recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 2003;290(17):2292\u2013300.","journal-title":"JAMA"},{"issue":"9","key":"5502_CR29","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1001\/jama.291.9.1071","volume":"291","author":"SE Nissen","year":"2004","unstructured":"Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, Crowe T, Howard G, Cooper CJ, Brodie B, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291(9):1071\u201380.","journal-title":"JAMA"},{"issue":"21","key":"5502_CR30","doi-asserted-by":"publisher","first-page":"3372","DOI":"10.1161\/01.CIR.0000147777.12010.EF","volume":"110","author":"JC Tardif","year":"2004","unstructured":"Tardif JC, Gr\u00e9goire J, L\u2019Allier PL, Anderson TJ, Bertrand O, Reeves F, Title LM, Alfonso F, Schampaert E, Hassan A, et al. Effects of the acyl coenzyme a:cholesterol acyltransferase inhibitor Avasimibe on human atherosclerotic lesions. Circulation. 2004;110(21):3372\u20137.","journal-title":"Circulation"},{"issue":"1","key":"5502_CR31","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/BF02693934","volume":"9","author":"M Clearfield","year":"2007","unstructured":"Clearfield M. Effect of very high intensity Statin therapy on regression of coronary atherosclerosis. Curr Atheroscler Rep. 2007;9(1):6\u20138.","journal-title":"Curr Atheroscler Rep"},{"issue":"22","key":"5502_CR32","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1001\/jama.2016.16951","volume":"316","author":"SJ Nicholls","year":"2016","unstructured":"Nicholls SJ, Puri R, Anderson T, Ballantyne CM, Cho L, Kastelein JJ, Koenig W, Somaratne R, Kassahun H, Yang J, et al. Effect of Evolocumab on progression of coronary disease in Statin-Treated patients: the GLAGOV randomized clinical trial. JAMA. 2016;316(22):2373\u201384.","journal-title":"JAMA"},{"issue":"17","key":"5502_CR33","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1016\/j.jacc.2018.06.078","volume":"72","author":"SJ Nicholls","year":"2018","unstructured":"Nicholls SJ, Puri R, Anderson T, Ballantyne CM, Cho L, Kastelein JJP, Koenig W, Somaratne R, Kassahun H, Yang J, et al. Effect of Evolocumab on coronary plaque composition. J Am Coll Cardiol. 2018;72(17):2012\u201321.","journal-title":"J Am Coll Cardiol"},{"issue":"3 Suppl","key":"5502_CR34","doi-asserted-by":"publisher","first-page":"S95","DOI":"10.1016\/j.jcmg.2011.08.024","volume":"5","author":"EA Sanidas","year":"2012","unstructured":"Sanidas EA, Mintz GS, Maehara A, Cristea E, Wennerblom B, I\u00f1iguez A, Fajadet J, Fahy M, Dressler O, Weisz G, et al. Adverse cardiovascular events arising from atherosclerotic lesions with and without angiographic disease progression. JACC Cardiovasc Imaging. 2012;5(3 Suppl):S95\u2013105.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"1","key":"5502_CR35","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s12872-019-1173-5","volume":"19","author":"YH Seo","year":"2019","unstructured":"Seo YH, Kim YK, Song IG, Kim KH, Kwon TG, Bae JH. Long-term clinical outcomes in patients with untreated non-culprit intermediate coronary lesion and evaluation of predictors by using virtual histology-intravascular ultrasound; a prospective cohort study. BMC Cardiovasc Disord. 2019;19(1):187.","journal-title":"BMC Cardiovasc Disord"},{"issue":"4 Suppl","key":"5502_CR36","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1161\/01.CIR.51.4.5","volume":"51","author":"WG Austen","year":"1975","unstructured":"Austen WG, Edwards JE, Frye RL, Gensini GG, Gott VL, Griffith LS, McGoon DC, Murphy ML, Roe BB. A reporting system on patients evaluated for coronary artery disease. Report of the ad hoc committee for grading of coronary artery Disease, Council on cardiovascular Surgery, American heart association. Circulation. 1975;51(4 Suppl):5\u201340.","journal-title":"Circulation"},{"key":"5502_CR37","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.atherosclerosis.2019.08.014","volume":"290","author":"2019 ESC\/EAS guidelines for the","year":"2019","unstructured":"2019 ESC\/EAS guidelines for the. Management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019;290:140\u2013205.","journal-title":"Atherosclerosis"},{"issue":"1","key":"5502_CR38","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1161\/01.ATV.1.1.38","volume":"1","author":"S Stender","year":"1981","unstructured":"Stender S, Zilversmit DB. Transfer of plasma lipoprotein components and of plasma proteins into aortas of cholesterol-fed rabbits. Molecular size as a determinant of plasma lipoprotein influx. Arteriosclerosis. 1981;1(1):38\u201349.","journal-title":"Arteriosclerosis"},{"key":"5502_CR39","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.atherosclerosis.2018.06.881","volume":"275","author":"P Zanoni","year":"2018","unstructured":"Zanoni P, Velagapudi S, Yalcinkaya M, Rohrer L, von Eckardstein A. Endocytosis of lipoproteins. Atherosclerosis. 2018;275:273\u201395.","journal-title":"Atherosclerosis"},{"issue":"3","key":"5502_CR40","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/0021-9150(80)90129-X","volume":"35","author":"G Camejo","year":"1980","unstructured":"Camejo G, Lalaguna F, L\u00f3pez F, Starosta R. Characterization and properties of a lipoprotein-complexing proteoglycan from human aorta. Atherosclerosis. 1980;35(3):307\u201320.","journal-title":"Atherosclerosis"},{"issue":"2","key":"5502_CR41","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S0021-9150(98)00107-5","volume":"139","author":"G Camejo","year":"1998","unstructured":"Camejo G, Hurt-Camejo E, Wiklund O, Bondjers G. Association of Apo B lipoproteins with arterial proteoglycans: pathological significance and molecular basis. Atherosclerosis. 1998;139(2):205\u201322.","journal-title":"Atherosclerosis"},{"issue":"12","key":"5502_CR42","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1172\/JCI2265","volume":"101","author":"J Bor\u00e9n","year":"1998","unstructured":"Bor\u00e9n J, Olin K, Lee I, Chait A, Wight TN, Innerarity TL. Identification of the principal proteoglycan-binding site in LDL. A single-point mutation in apo-B100 severely affects proteoglycan interaction without affecting LDL receptor binding. J Clin Invest. 1998;101(12):2658\u201364.","journal-title":"J Clin Invest"},{"issue":"6890","key":"5502_CR43","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1038\/nature00804","volume":"417","author":"K Sk\u00e5l\u00e9n","year":"2002","unstructured":"Sk\u00e5l\u00e9n K, Gustafsson M, Rydberg EK, Hult\u00e9n LM, Wiklund O, Innerarity TL, Bor\u00e9n J. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature. 2002;417(6890):750\u20134.","journal-title":"Nature"},{"issue":"16","key":"5502_CR44","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1161\/CIRCULATIONAHA.106.676890","volume":"116","author":"I Tabas","year":"2007","unstructured":"Tabas I, Williams KJ, Bor\u00e9n J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation. 2007;116(16):1832\u201344.","journal-title":"Circulation"},{"issue":"7","key":"5502_CR45","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1172\/JCI0216452","volume":"110","author":"I Tabas","year":"2002","unstructured":"Tabas I. Consequences of cellular cholesterol accumulation: basic concepts and physiological implications. J Clin Invest. 2002;110(7):905\u201311.","journal-title":"J Clin Invest"},{"issue":"3","key":"5502_CR46","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.cell.2011.04.005","volume":"145","author":"KJ Moore","year":"2011","unstructured":"Moore KJ, Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell. 2011;145(3):341\u201355.","journal-title":"Cell"},{"issue":"6917","key":"5502_CR47","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/nature01323","volume":"420","author":"P Libby","year":"2002","unstructured":"Libby P. Inflammation in atherosclerosis. Nature. 2002;420(6917):868\u201374.","journal-title":"Nature"},{"issue":"1","key":"5502_CR48","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/0735-1097(88)90356-7","volume":"12","author":"JA Ambrose","year":"1988","unstructured":"Ambrose JA, Tannenbaum MA, Alexopoulos D, Hjemdahl-Monsen CE, Leavy J, Weiss M, Borrico S, Gorlin R, Fuster V. Angiographic progression of coronary artery disease and the development of myocardial infarction. J Am Coll Cardiol. 1988;12(1):56\u201362.","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"5502_CR49","doi-asserted-by":"publisher","first-page":"2979","DOI":"10.1016\/j.jacc.2017.10.024","volume":"70","author":"L Fern\u00e1ndez-Friera","year":"2017","unstructured":"Fern\u00e1ndez-Friera L, Fuster V, L\u00f3pez-Melgar B, Oliva B, Garc\u00eda-Ruiz JM, Mendiguren J, Bueno H, Pocock S, Ib\u00e1\u00f1ez B, Fern\u00e1ndez-Ortiz A, et al. Normal LDL-Cholesterol levels are associated with subclinical atherosclerosis in the absence of risk factors. J Am Coll Cardiol. 2017;70(24):2979\u201391.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"5502_CR50","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1161\/01.CIR.0000150335.01285.12","volume":"111","author":"R Glaser","year":"2005","unstructured":"Glaser R, Selzer F, Faxon DP, Laskey WK, Cohen HA, Slater J, Detre KM, Wilensky RL. Clinical progression of incidental, asymptomatic lesions discovered during culprit vessel coronary intervention. Circulation. 2005;111(2):143\u20139.","journal-title":"Circulation"},{"issue":"17","key":"5502_CR51","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1001\/jama.2014.14681","volume":"312","author":"TM Maddox","year":"2014","unstructured":"Maddox TM, Stanislawski MA, Grunwald GK, Bradley SM, Ho PM, Tsai TT, Patel MR, Sandhu A, Valle J, Magid DJ, et al. Nonobstructive coronary artery disease and risk of myocardial infarction. JAMA. 2014;312(17):1754\u201363.","journal-title":"JAMA"},{"issue":"9","key":"5502_CR52","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1161\/ATVBAHA.115.305874","volume":"35","author":"LB Steffensen","year":"2015","unstructured":"Steffensen LB, Mortensen MB, Kjolby M, Hagensen MK, Oxvig C, Bentzon JF. Disturbed laminar blood flow vastly augments lipoprotein retention in the artery wall: A key mechanism distinguishing susceptible from resistant sites. Arterioscler Thromb Vasc Biol. 2015;35(9):1928\u201335.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"5502_CR53","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.atherosclerosis.2015.01.039","volume":"239","author":"MR Taskinen","year":"2015","unstructured":"Taskinen MR, Bor\u00e9n J. New insights into the pathophysiology of dyslipidemia in type 2 diabetes. Atherosclerosis. 2015;239(2):483\u201395.","journal-title":"Atherosclerosis"},{"issue":"6","key":"5502_CR54","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.2337\/diacare.27.6.1496","volume":"27","author":"RM Krauss","year":"2004","unstructured":"Krauss RM. Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care. 2004;27(6):1496\u2013504.","journal-title":"Diabetes Care"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-026-05502-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-05502-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-05502-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T16:03:37Z","timestamp":1770653017000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12872-026-05502-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,13]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5502"],"URL":"https:\/\/doi.org\/10.1186\/s12872-026-05502-8","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,13]]},"assertion":[{"value":"5 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All methods were carried out in accordance with the Declaration of Helsinki. This study was approved by the Ethics Committee of the First Affiliated Hospital of Xinjiang Medical University (approval number: 220525-06). The need for written informed consent was waived by the Ethics Committee of the First Affiliated Hospital of Xinjiang Medical University due to the retrospective nature of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"129"}}